We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Results of National Breast Cancer Screening Program in Norway Published

By HospiMedica International staff writers
Posted on 06 Jul 2015
The results of a research-based evaluation of the Norwegian Breast Cancer Screening program, conducted between 2007 and 2015 show a dramatic reduction in mortality as a result of the program.

The program, which was conducted by The Research Council of Norway, indicates a reduction of mortality of between 20% and 30% for women in the age group 50–69, and followed to age 79, that were screened for breast cancer every other year, compared to those that were not screened. More...
The results correlate with those of the majority of previous mammography screening trial reviews.

The objective of the evaluation was to find out whether the Norwegian Breast Cancer Screening program achieved its primary goal of a 30% reduction in breast cancer-related mortality or not. The evaluation also recorded the extent of over diagnosis, the women's screening experience, and the cost-effectiveness of the program.

The program was launched as a pilot project in four Norwegian counties in 1995/1996 and became a national program in 2004, with the purpose of detecting tumors earlier. For every 10,000 women invited to 10 rounds of screening, approximately 377 cases of tumors or pre-malignant breast lesions were detected, and approximately 27 lives were saved as a result of early diagnosis and treatment. Approximately 142 women were over-diagnosed.

Prof. Roar Johnsen of the Norwegian University of Science and Technology (NTNU), said, “The most reliable studies indicate a 20% to 30% reduction in breast cancer mortality in women aged 50 to 69 who have been followed up until the age of 79. This reduction can be said to be close to the primary target of 30%. There is a large degree of uncertainty with these figures. Each woman must weigh the advantages and disadvantages of her own situation when deciding whether to accept the offer of free screening.”

Related Links:

The Research Council of Norway



Gold Member
12-Channel ECG
CM1200B
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Monitor/Defibrillator
Zenix
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Graphical Abstract (Aoibhin M. Sheedy et al., A replenishable peritoneal implant for localized delivery and peritoneal fluid sampling in ovarian cancer, Device (2026). DOI: 10.1016/j.device.2026.101050)

New Implant Provides Sustained Localized Therapy for Ovarian Cancer

Ovarian cancer is often diagnosed at advanced stages because symptoms such as bloating, pain, and pelvic pressure are nonspecific. Standard care relies on surgery and systemic therapy, yet tools for targeted... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.